Home  /  Resource Library  /  Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trials

Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trials

Retrospective study examined poloatuzumab vedotin combined with chemoimmunotherapy for first line treatment of DLBCL.

Related Articles

Editorial Guidelines

To ensure the integrity of all content produced by the Lymphoma Coalition (LC), a rigorous process has been put

Learn More

Transparency With Corporations...

This document outlines LC’s policy on commercial funding and provides a set of principles that will be used to guide LC’s decisions. It does not...

Learn More